Stifel’s Mid-2024 Halftime Report, packed with DealForma data, on the biotech market highlights the mixed investor sentiment, strong mid-sized M&A activity, improving inflation, and a predicted robust but bumpy market recovery for the rest of the year. Explore Stifel’s research.
